Acral myxoinflammatory fibroblastic sarcoma

Lore & Background

AMSF tumors commonly develop in the subcutaneous tissues of the arms or legs of adults, with about two-thirds of cases occurring in a finger, hand, wrist, foot, or ankle. Individuals typically present with a painless, slowly growing mass. The size of these tumors has ranged from 1.5 to 18 cm, with exceptional cases reaching 25 cm or 30 cm in maximum diameter. Recurrence at the site of previous surgical removal is common, occurring in 22% to 67% of cases, and repeated recurrences are treated with repeated surgical resections.

Reader's Guide

AMSF is significant as a diagnostic challenge due to its highly variable microscopic appearances, which include large epithelioid cells, lipoblast-like cells, and a prominent inflammatory infiltrate. These features can lead to confusion with other myxoid-rich soft tissue tumors such as myxoid liposarcoma, myxofibrosarcoma, and extra-skeletal myxoid chondrosarcoma. Diagnosis rests primarily on patient presentation and histopathology, as immunostaining and genetic abnormalities are non-specific. Treatment is surgical resection with wide margins; radiation therapy may aid local control, but chemotherapy has not been shown useful. The tumor's low metastatic rate (1–2%) contrasts with its high local recurrence rate, making long-term follow-up important.

Did You Know?

• AMSF tumors have been reported in individuals aged 4 to 91 years.
• In one large study, emperipolesis of white blood cells appeared to be a helpful indicator of AMSF.
• AMSF tumors may contain cells termed Reed-Sternberg cell-like, virocyte-like, and ganglion cell-like.
• The tumor was first described in 1998 independently in three publications.

Clinical Presentation & Demographics

AMSF is an exceedingly rare neoplasm, affecting roughly one in a million individuals, with no meaningful difference in frequency between men and women. Although the average age at presentation sits around forty years, documented cases span a remarkably wide range from a four-year-old to a ninety-one-year-old. The tumor most frequently arises in the subcutaneous tissue of the distal, posterior aspects of the limbs. Approximately two-thirds of all cases are found in the fingers, hands, wrists, feet, or ankles, while a smaller subset involves the upper arm, thigh, shoulder, groin, upper back, neck, temple, and in one exceptional report, the nose. Patients typically notice a painless, slowly enlarging mass. Reported sizes range from 1.5 to 18 centimeters, though two extraordinary outliers measured 25 and 30 centimeters in their greatest dimension. Because the lesion is locally aggressive, many individuals return to the clinic with a recurrence at the prior surgical site, and in rare instances present with distant metastatic disease.

Histopathology & Microscopic Complexity

Under the microscope, AMSF presents a bewildering mosaic of cell types that has long confounded pathologists. The tumor is typically lobulated and may appear gelatinous, fleshy, or firm, most often residing in subcutaneous fat but sometimes infiltrating adjacent structures. Hematoxylin-and-eosin staining reveals spindle-shaped cells intermingled with conspicuous inflammatory zones populated by neutrophils, lymphocytes, and plasma cells. Interspersed among these are strikingly large epithelioid cells bearing vesicle-laden nuclei and prominent acidophilic nucleoli, which have been compared to Reed-Sternberg cells, virocytes, and ganglion cells. Vacuolated pseudolipoblasts, degenerating or dead cells, and large histiocyte-like cells performing emperipolesis—engulfing intact white blood cells—may also be present, all set within a myxoid, collagen-rich stroma. The proportions of each cell type shift dramatically from one specimen to the next. In some cases, dense inflammatory infiltrates completely obscure the neoplastic cells, making the lesion mimic a purely reactive inflammatory process and posing a serious diagnostic pitfall.

Treatment & Prognosis

The World Health Organization's 2020 classification places AMSF among the rarely metastasizing fibroblastic and myofibroblastic tumors, a designation that captures its dual nature: locally tenacious yet, in the vast majority of cases, confined to the region of origin. Distant dissemination occurs in only one to two percent of patients, and the tumor generally grows at a slow pace. The cornerstone of management is wide surgical excision aimed at clearing every visible and microscopic trace of neoplastic tissue, thereby minimizing the risk of local recurrence. When the tumor reappears at the previous operative site, the standard response is another round of resection, and this cycle of surgery can repeat multiple times. In the most refractory scenarios, clinicians have resorted to combining postoperative radiation with surgical removal, or even amputating the affected limb. Notably, systemic chemotherapy has not demonstrated any meaningful benefit for localized, recurrent, or metastatic AMSF, leaving surgery as the principal therapeutic tool.

Molecular & Genetic Landscape

Despite the rarity of AMSF, researchers have identified a scattered collection of chromosomal and genetic alterations in a minority of cases. These include losses involving chromosome 3 or chromosome 13, a translocation pairing the TGFBR3 gene on the short arm of chromosome 1 with the MGEA5 gene on the long arm of chromosome 10, a ring chromosome linked to overexpression of the VGLL3 and CHMP2B proteins, and incompletely characterized fusions involving the BRAF gene on chromosome 7. Immunohistochemical profiling has yielded inconsistent results across studies: vimentin expression is nearly universal, while MUC1, CD31, CD34, CD68, and PDPN appear variably, and markers such as CD45, CD15, CD30, HMB-45, Melan-A, desmin, GFAP, and S100 are typically absent. Because none of these molecular or protein-expression patterns are specific to AMSF, they have not proven reliable for diagnosis. Consequently, distinguishing AMSF from look-alike entities such as myxoid liposarcoma, myxofibrosarcoma, and extra-skeletal myxoid chondrosarcoma still depends heavily on clinical context and careful histopathologic interpretation.